Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

Rhea-AI Summary

Emergent BioSolutions (NYSE: EBS) has secured approximately $27 million in international orders for delivery in 2025 for its medical countermeasures (MCM) portfolio. The orders focus on products addressing potential smallpox and anthrax threats, contributing to international market supply.

Joe Papa, president and CEO, emphasized Emergent's role as a trusted partner in supplying communities with protective medical countermeasures. The company plans to continue its international expansion efforts as part of its multi-year transformation plan, strengthening health preparedness globally.

Emergent specializes in developing, manufacturing, and supplying MCMs for national security and public health preparedness, enabling governments to respond effectively to emergencies and protect against potential threats.

Positive

• Secured $27 million in new international orders for 2025
• Expansion of international market presence
• Diversification of revenue streams through multiple MCM products

Negative

• None.

GAITHERSBURG, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has recently secured approximately $27 million in international orders targeted for delivery in 2025 associated with its medical countermeasures (MCM) portfolio. These orders will help address potential threats of smallpox and anthrax and will contribute to the overall supply of MCM’s to the international market in 2025.

“Emergent is a trusted partner to supply communities around the world with medical countermeasures that protect against serious health threats like smallpox and anthrax,” said Joe Papa, president and CEO of Emergent. “We are pleased to engage and support global partners in fulfilling their preparedness needs. As part of our multi-year transformation plan, we will continue to focus on international expansion efforts and strengthening health preparedness at home and abroad.”

Emergent specializes in developing, manufacturing, and supplying MCMs for national security and public health preparedness. These products enable governments to effectively respond to emergencies and protect the public from potential threats. The types and quantities of products that should be maintained in a stockpile will depend on the population requiring protection, the products available for meeting the threat, as well as government resources and priorities.

About Emergent BioSolutions

At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

FAQ

What is the value of Emergent BioSolutions' (EBS) new international orders for 2025?

Emergent BioSolutions secured approximately $27 million in international orders for medical countermeasure products, scheduled for delivery in 2025.

Which specific threats do EBS's new medical countermeasure orders address?

The orders are for products that address potential threats of smallpox and anthrax.

How does this order align with Emergent BioSolutions' (EBS) strategic plans?

The orders align with EBS's multi-year transformation plan, which focuses on international expansion efforts and strengthening global health preparedness.

When will Emergent BioSolutions (EBS) deliver these new international orders?

The orders are targeted for delivery in 2025.